These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3457987)

  • 1. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium carbonate: a suitable alternative to aluminum hydroxide as phosphate binder.
    Malberti F; Surian M; Colussi G; Poggio F; Minoia C; Salvadeo A
    Kidney Int Suppl; 1988 Mar; 24():S184-5. PubMed ID: 3163047
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
    N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 6. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 7. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 8. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 9. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.
    Moriniere P; Roussel A; Tahiri Y; de Fremont JF; Maurel G; Jaudon MC; Gueris J; Fournier A
    Proc Eur Dial Transplant Assoc; 1983; 19():784-7. PubMed ID: 6878265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
    Wikström B; Danielson BG; Fellström B
    Adv Perit Dial; 1991; 7():221-4. PubMed ID: 1680430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aluminum hydroxide treatment of hyperphosphatemia in uremia].
    Bergquist-Poppen M; Bergström J; Wallin R
    Lakartidningen; 1972 May; 69(19):2319-20. PubMed ID: 5035811
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder.
    Malberti F; Surian M; Poggio F; Minoia C; Salvadeo A
    Am J Kidney Dis; 1988 Dec; 12(6):487-91. PubMed ID: 3143260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal osteodystrophy in children: progress in its management.
    Chan JC
    Clin Pediatr (Phila); 1976 Nov; 15(11):996-1002. PubMed ID: 975714
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of hyperphosphatemia in chronic renal failure].
    Babarykin DA; Afanas'eva GA; Shul'man OM; Luse LIa; Rozental' RL
    Ter Arkh; 1984; 56(7):64-6. PubMed ID: 6484838
    [No Abstract]   [Full Text] [Related]  

  • 16. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevent hyperphosphatemia in a child on hemodialysis.
    Drukker A
    Pediatr Nephrol; 1997 Oct; 11(5):661. PubMed ID: 9323304
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium carbonate as a phosphate binder. One year's experience.
    Kobrin SM; Epstein SE; Goldstein SJ; Kramer MS; Raja RM
    ASAIO Trans; 1987; 33(3):518-20. PubMed ID: 3314935
    [No Abstract]   [Full Text] [Related]  

  • 19. The treatment of uremic hyperphosphatemia.
    Schaefer K
    Clin Nephrol; 1996 Oct; 46(4):279-80. PubMed ID: 8905221
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcium carbonate. A better phosphate binder than aluminum hydroxide.
    Lerner A; Kramer M; Goldstein S; Caruana R; Epstein S; Raja R
    ASAIO Trans; 1986; 32(1):315-8. PubMed ID: 3535845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.